Colorectal Adenocarcinoma

Therapeutic response

Precision oncology relationships for therapeutic response involving this cancer type.

Organization(s)	Biomarker(s)	Cancer type	Therapy(ies)
FDA (1) HC (1)	EGFR positive, Wild type KRAS	Colorectal Adenocarcinoma	Cetuximab, Fluorouracil, Irinotecan
FDA (1) HC (1)	EGFR positive, Wild type KRAS	Colorectal Adenocarcinoma	Cetuximab, Irinotecan
FDA (1) HC (2)	EGFR positive, Wild type KRAS	Colorectal Adenocarcinoma	Cetuximab
FDA (2) HC (1)	BRAF p.V600E	Colorectal Adenocarcinoma	Cetuximab, Encorafenib
FDA (2)	MSI-H	Colorectal Adenocarcinoma	Ipilimumab, Nivolumab
FDA (1)	Wild type HRAS, Wild type KRAS	Colorectal Adenocarcinoma	Fluorouracil, Oxaliplatin, Panitumumab
FDA (1)	Wild type HRAS, Wild type KRAS	Colorectal Adenocarcinoma	Panitumumab
FDA (1) HC (1)	dMMR	Colorectal Adenocarcinoma	Pembrolizumab
FDA (1) HC (1)	MSI-H	Colorectal Adenocarcinoma	Pembrolizumab
FDA (1)	KRAS p.G12C	Colorectal Adenocarcinoma	Adagrasib, Cetuximab
FDA (2)	dMMR	Colorectal Adenocarcinoma	Ipilimumab, Nivolumab
FDA (1)	MSI-H	Colorectal Adenocarcinoma	Nivolumab
FDA (1)	dMMR	Colorectal Adenocarcinoma	Nivolumab
FDA (1)	BRAF p.V600E	Colorectal Adenocarcinoma	Cetuximab, Encorafenib, Fluorouracil, Oxaliplatin
HC (1)	Wild type KRAS, Wild type NRAS	Colorectal Adenocarcinoma	Panitumumab
FDA (1)	HER2-positive, Wild type KRAS, Wild type NRAS	Colorectal Adenocarcinoma	Trastuzumab, Tucatinib